Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Markets & Finance

Morgan Stanley Cuts Boston Scientific to 'Equal-Weight'

Morgan Stanley downgraded Boston Scientific (BSX) to equal-weight from overweight.

says he cut his rating because he believes that Boston Scientific, unlike most medical technology companies, will probably hit a peak earnings cycle sometime in 2005 as new competition emerges from Guidant and Medtronics. He also notes Boston Scientific remains vulnerable on patent issues relating to its stent technology.

Meanwhile, Reicin expects the company's Taxus IV drug-eluting stent data, to be presented in September, to be a favorable event for the company and its earnings outlook. As such, he upgraded the $2.55 2004 earnings per share estimate to $3.28, and upgraded the $2.93 2005 earnings per share estimate to $3.75, but sees the 2006 earnings per share estimate slipping to $3.08. Finally, Reicin upgraded his $69 target to $75.

blog comments powered by Disqus